E-LIB Suche - Ergebnisse für: Setze, Carolyn

1

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in ..:

Gane, Edward ; Poordad, Fred ; Zadeikis, Neddie...
Clinical Infectious Diseases. 69 (2019) 10 - p. 1657-1664 , 2019

Link: https://doi.org/10.1093/..

2

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonav..:

Sato, Ken ; Chayama, Kazuaki ; Alves, Katia...
Advances in Therapy. 34 (2017) 6 - p. 1449-1465 , 2017

Link: https://doi.org/10.1007/..

3

Resistance characterization of hepatitis C virus genotype 2..:

Schnell, Gretja ; Tripathi, Rakesh ; Krishnan, Preethi...
Journal of Medical Virology. 90 (2017) 1 - p. 109-119 , 2017

Link: https://doi.org/10.1002/..

4

Analysis of Hepatitis C Virus Genotype 1b Resistance Varian..:

Krishnan, Preethi ; Schnell, Gretja ; Tripathi, Rakesh...
Antimicrobial Agents and Chemotherapy. 60 (2016) 2 - p. 1106-1113 , 2016

Link: https://doi.org/10.1128/..

5

Randomized trial of interferon‐ and ribavirin‐free ombitasv..:

Chayama, Kazuaki ; Notsumata, Kazuo ; Kurosaki, Masayuki...
Hepatology. 61 (2015) 5 - p. 1523-1532 , 2015

Link: https://doi.org/10.1002/..

6

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonav..:

Kumada, Hiromitsu ; Chayama, Kazuaki ; Rodrigues, Lino...
Hepatology. 62 (2015) 4 - p. 1037-1046 , 2015

Link: https://doi.org/10.1002/..

7

Study Design, Rationale, and Baseline Characteristics: Eval..:

Davidson, Michael ; Rosenson, Robert S. ; Maki, Kevin C....
Cardiovascular Drugs and Therapy. 26 (2012) 4 - p. 349-358 , 2012

Link: https://doi.org/10.1007/..

8

Lipid Target Attainment by Switching Statin Monotherapy to ..:

Jones, Peter H. ; Mohiuddin, Syed ; Ballantyne, Christie...
Journal of Clinical Lipidology. 5 (2011) 3 - p. 202-203 , 2011

Link: https://doi.org/10.1016/..

9

Effects of Fenofibric Acid in Combination with Statin Thera..:

Jones, Peter H. ; Dayspring, Thomas ; Setze, Carolyn...
Journal of Clinical Lipidology. 5 (2011) 3 - p. 202 , 2011

Link: https://doi.org/10.1016/..

10

Long-Term Effects of Fenofibric Acid + Statin Combination T..:

Thakker, Kamlesh ; Mandair, Inderjit ; Setze, Carolyn..
Journal of Clinical Lipidology. 5 (2011) 3 - p. 228 , 2011

Link: https://doi.org/10.1016/..

11

Baseline VLDL-C is Significantly Associated with Triglyceri..:

Joshi, Parag ; Voros, Szilard ; Rinhart, Sarah...
Journal of Clinical Lipidology. 5 (2011) 3 - p. 228-229 , 2011

Link: https://doi.org/10.1016/..

12

A Randomized, Double-Blind Study of Fenofibric Acid Plus Ro..:

Weinstein, Debra L. ; Williams, Laura A. ; Carlson, Dawn M....
Clinical Therapeutics. 35 (2013) 8 - p. 1186-1198 , 2013

Link: https://doi.org/10.1016/..

13

Attainment of goal/desirable lipid levels in patients with ..:

Roth, Eli M. ; Rosenson, Robert S. ; Jones, Peter H....
Journal of Clinical Lipidology. 6 (2012) 6 - p. 534-544 , 2012

Link: https://doi.org/10.1016/..

14

Efficacy and Safety of Fenofibric Acid + Rosuvastatin Versu..:

Weinstein, Debra L. ; Williams, Laura A. ; Carlson, Dawn M....
Journal of Clinical Lipidology. 6 (2012) 3 - p. 269-270 , 2012

Link: https://doi.org/10.1016/..

15

One-Year Efficacy and Safety of Rosuvastatin + Fenofibric A..:

Ferdinand, Keith C. ; Davidson, Michael H. ; Kelly, Maureen T..
American Journal Cardiovascular Drugs. 12 (2012) 2 - p. 117-125 , 2012

Link: https://doi.org/10.2165/..